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Abstract: Hairy cell leukemia (HCL) is an uncommon B-cell chronic lymphoproliferative
disorder whose pathogenesis and recurrence are strictly dependent on the presence of the
BRAF V600E mutant. A 65-year-old male presented a monomorphic epitheliotropic intest-
inal T-cell lymphoma (formerly enteropathy-associated T-cell lymphoma, type II) with HCL
not responding to first-line induction with cladribine. The intestinal lymphoma bears the
BRAF V600E mutant, which is the molecular hallmark of HCL, being implicated in its
pathogenesis. The case is of interest, as it provides the first description of a BRAF V600E-
positive intestinal T-cell lymphoma, along with immunohistochemical and molecular demon-
stration, occurring in concomitance with HCL. A novel digital PCR-base method for HCL
disease assessment is also suggested.
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Introduction
Hairy cell leukemia (HCL) is an uncommon B-cell chronic lymphoproliferative
disorder whose pathogenesis and recurrence are strictly dependent on the presence
of the BRAF V600E mutant, a pivotal player in the mitogen-activated protein (MAP)
kinase pathway.1,2 The molecular landscape of HCL is rather simple: mutant BRAF is
found in all cases and the same mutation persists during subsequent relapses.1 It is
regarded as the sole molecular abnormality able to confer the leukemic phenotype by
enhancing an autonomous cellular proliferation and inhibiting apoptosis.1 For this
reason, mutated BRAF can be considered an effective therapeutic target: good
responses are rapidly obtained in patients with relapsed disease treated with vemur-
afenib, a BRAF inhibitor.3 Although experiences with BRAF inhibitors are encoura-
ging, first-line treatment is still based on purine analogs (cladribine and pentostatin),
with up to 90% of complete responses. Even if outcomes are so favorable with
induction therapy, patients tend to relapse over time and approximately 40% of them
experience disease recurrence within 10 years.4,5
Despite the great biological importance of the BRAF gene mutation in this
context, this seems to be quite a unique feature of HCL. Although BRAF-
mutated non-Hodgkin lymphomas (NHL) have been described, mutations involving
codon 600 are borne in just a minority of cases (2–16%, according to different case
series) and never as a unique aberration.6,7 A few cases of BRAF V600E-positive
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chronic lymphocytic leukemia have been described, and
some BRAF mutants have been identified in patients with
Richter’s transformation.8
Here, we present an almost unique case of concomitant
diagnosis of HCL and monomorphic epitheliotropic intest-
inal T-cell lymphoma (MEITL) in a patient who was
refractory to cladribine.
Case report
A 65-year-old Caucasian man, with a history of mild
thrombocytopenia (interpreted as immune) known since
2013 and never treated, was referred to our institution in
August 2016 because of the recent appearance of petechiae
at both lower limbs, without extension to the trunk or arms
and without mucosal or major hemorrhage. Splenomegaly
was detected upon physical examination.
Blood tests revealed severe neutropenia, with 1,950
leukocytes/mm3 (30% neutrophils), mild anemia (hemoglo-
bin was 11.4 g/dL), and severe thrombocytopenia (platelets
were 47,000/mm3). The biochemical profile demonstrated
a mild increase of creatinine, 1.47 mg/dL, with no further
abnormal findings. A bone marrow biopsy was performed,
showing a marked hypocellularity (15%), along with an
interstitial and diffuse infiltrate (90% of cellularity) com-
posed of small lymphocytes with abundant pale cytoplasm
and round-to-oval nuclei and a grade 1 marrow fibrosis. The
immunohistochemical evaluation showed positivity for
CD20 and annexin A1 (ANXA1). A droplet digital polymer-
ase chain reaction assay performed on peripheral blood
mononuclear cells demonstrated the presence of the BRAF
V600E mutation, with a fractional abundance of the mutated
allele (which denotes the proportion of the mutant allele
frequencies) of 37.9%. A diagnosis of HCL was made.
Subcutaneous cladribine was started in
September 2016 at the total dose of 10 mg to be delivered
once a week for 5 consecutive weeks. The day before
the second injection, the patient was admitted to the emer-
gency room because of fever, chills, and right testis ten-
derness. A diagnosis of febrile neutropenia with
orchiepididymitis was made. Bilateral pleural effusion,
without pulmonary infiltrates, was evident at high-
resolution computed tomography scan; ascites was also
documented upon abdominal ultrasound. The patient
rapidly became anuric. Biochemical tests showed marked
hypercreatininemia (5.6 mg/dL), hyperkaliemia (6.9 mEq/
L), and metabolic acidosis. Blood cultures were negative
for aerobic or anaerobic bacteria and galactomannans were
negative.
Awide-spectrum antibiotic treatment was started, along
with furosemide and albumin supplementation to reduce the
ascitic fluid. A diagnostic paracentesis demonstrated an
exudate with no hairy cells. Fluid balance, diuretics, and
electrolyte correction allowed a complete recovery from
acute renal failure. Intravenous methylprednisolone was
started at this point, with an initial clinical and laboratory
improvement. Nevertheless, a sudden acute respiratory fail-
ure developed soon after due to acute pulmonary edema.
Non-invasive ventilation and diuretics could restore an
adequate respiratory function, and the patient was again
addressed to subcutaneous cladribine administration in
November 2016 (2 months after the first dose). At this
point, it was decided to administer cladribine once a day
for 5 consecutive days. Fifty days after treatment comple-
tion, cytopenia had not resolved, as leukocytes were still
lower than 1,000/mm3 and neutrophils <500/mm3 irrespec-
tive of granulocyte colony-stimulating factor support.
Thrombocytopenia also persisted (70,000/mm3), along
with splenomegaly, pleural effusions, and ascites. A hairy
cell marrow infiltration was confirmed (Figure 1, Panels
A-B), and the BRAF V600E fractional abundance remained
persistently high (10.33%), indicating a lack of response.
Less than 1 month later, the patient was admitted again to
the emergency department because of acute abdominal pain,
diarrhea, and clinical signs of bowel perforation. An emer-
gency exploratory laparotomy revealed jejunal perforation,
which prompted the resection of 9 cm of affected small
bowel. The resected intestinal wall was extensively infil-
trated by CD20−, PAX5−, CD3+, CD4−, CD8+, and
ANXA1− lymphoid elements, with a Ki-67 of 70%. CD56
and TIA-1 were also positive (Figure 1, Panels C-G).
A diagnosis of MEITL was made. Interestingly, BRAF pyr-
osequencing on affected intestinal tissue showed a thymine
to adenine substitution at position 1,799, consistently with
the presence of the V600E mutant. Conversely, the mutation
was absent on unaffected resection margins (Figure 2, Panel
A), confirming a somatic – and not a germ-line – mutation.
The expression of mutant BRAF was also confirmed by
immunohistochemistry (Figure 1, Panels H-I). Molecular
analysis was performed on both biopsies (bone marrow
and intestine) to determine rearrangement of genes coding
for immunoglobulin heavy chains (IGH) and T-cell receptor
γ (TRG), trying to find out whether the two neoplasms
carried rearrangements of the same size. DNAwas extracted
and tested by control gene PCR (100–400 bp amplicons) to
verify its integrity. PCR assay was performed according to
EUROCLONALITY protocols and evaluated by
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GeneScanning analysis to determine clonal character. Both
samples presented low DNA quality and amount. Therefore,
it was possible to analyze only the frameshift region 3 (FR3)
of immunoglobulins, which showed the presence of
a reproducible 125 bp clone in both samples (Figure 2,
Panel B). The analysis of the TRG resulted partially unver-
ifiable, even if we obtained a polyclonal pattern in both
samples, the low quality of the material would have made
the comparison unreliable, according to euroclonality
guidelines.
The patient died in February 2017 due to an acute
episode of intestinal occlusion. A vemurafenib-based treat-
ment should have been taken into consideration if the
patient had survived.
Discussion
The simultaneous occurrence of T- and B-cell neoplasms is
exceptional and the etiologic and pathogenetic relationships
between the two phenotypically different malignancies are
not clear. An association between HCL and a T-cell NHL
has been described in a few cases,9–11 but all the reported
experiences could not provide any proof of a shared patho-
genesis of the two conditions. MEITL, previously sub-
classified as enteropathy-associated T-cell lymphoma type
II, is a rare (<1% of NHL) and primarily gastrointestinal
type of peripheral T-cell lymphoma with an aggressive
clinical course and a poor prognosis. MEITL shows
a unique genomic profile, characterized by recurrent muta-
tions of the SETD2 oncogene, along with deregulated JAK/
STAT pathway. The MAP-kinase pathway is also frequently
affected, as up to 80% of MEITL cases bear mutations of
TP53 (33%), BRAF (26%) and KRAS (20%).12
The co-occurrence of two rare malignancies leads us to
hypothesize a shared pathogenetic mechanisms, as it
seems unlikely a matter of chance. In other terms,
a common ontogenesis of the two neoplasms can be pos-
tulated. Given that BRAF mutation and IGH-FR3 rearran-
gement, as detected in this case, are mutually independent,
this observation strengthens the possible common onto-
geny of the two neoplasms. Nevertheless, it is hard to
discriminate whether they display a common origin versus
one neoplasm originates from the other as a result of
Figure 1 Microscopic appearance of the bone marrow (panels A and B) and of the affected intestinal wall after jejunal resection (panels C–I). Bone marrow immunohistochemistry
for CD20 and annexin A1, showing strong and diffuse positivity, is depicted in panels A and B, respectively. Panel C: hematoxylin-eosin staining. Panels D–F: immunohistochemistry
for CD3, CD56, and TIA-1, respectively. Panel G: negative immunohistochemistry for CD20 on affected intestinal tissue (no evidence of hairy cell leukemia cells). Panels H-I:
immunohistochemistry for BRAF V600E on intestinal tissue (panoramic and magnified view). Note BRAF negativity on unaffected intestinal tissue.
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transdifferentiation. This is because no technique is able to
reliably demonstrate this. To the best of our knowledge,
this is the first time that the same underlying molecular
lesion is found in MEITL concomitantly with active HCL,
ie, a disease that does not respond properly to induction
therapy. This reinforces the hypothesis that mutant BRAF
V600E may have played a role in the development and
progression of MEITL as well.
As it is known that BRAF gene mutations are found in
hematopoietic stem cells in patients with HCL, the
existence of a common progenitor is a possible explana-
tion for the case we described.13 Tumoral reprogramming
of an initiating HCL BRAF-mutated cell may also account
for tumor cell plasticity, ending up with a change of the
initial neoplastic phenotype and the development of
a secondary lymphoid disease, possibly favored by the
setting of profound immune suppression due to HCL itself,
its treatment and complications.14 Alternatively, a B-to-
T-cell dedifferentiation followed by phenotype conversion
can be another possible explanation.15 The presence of
Tumor
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Figure 2 Panel A: BRAF gene pyrosequencing on resected intestinal tissue, showing a T>A substitution in the affected tissue (upper diagram) and no mutation in unaffected
margins (lower diagram). Panel B: analysis of the frameshift region 3 (FR3) of immunoglobulins on both marrow and intestinal samples. Proof of evidence of a reproducible
125 bp clone in both samples.
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a shared IGH clone in both marrow and intestinal tissue –
in other words in both hairy cells and T-cell lymphoma
tissue – may support these theories.
Conclusion
This is an interesting case of concurrent HCL and MEITL
sharing the same genetic and phenotypic manifestation.
Importantly, the T-cell lymphoma was diagnosed later
than the initial HCL, when it became symptomatic. Since
that moment, in fact, the patient displayed the clinical and
laboratory features of HCL, although unexpected and
rather unusual complications (such as ascites) occurred
during treatment. The presence of the BRAF V600E
mutant and consequently of a disrupted MAP kinase path-
way, along with the demonstration of the same IGH rear-
rangement in both entities, can provide an explanation for
a shared pathogenesis of the two diseases.
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